MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
3. Government_Funders & Regulators
*Government: International
Europe
*Europe: Regions
*Western Europe
Ireland
*Industry: Ireland
Bristol-Myers Squibb Company (NYSE:BMY)
Organization & Developments: Bristol Myers Squibb (BMS)
Parents
Bristol-Myers Squibb Company (NYSE:BMY)
Children
*Bristol Myers Squibb: Brands
*CHF: Congestive Heart Failure
*Developments: Bristol Myers Squibb (BMS)
*Eliquis (apixaban)
*Fibrosis
*Immuno-oncology
*Immunoscience
*Opdivo (nivolumab)
*Organization: Bristol Myers Squibb
*Rare Disease
*Virology
2010: Exelixis Nabs $60M Upfront, Potentially $505M More, From New Deal With Bristol-Myers (2010)
2012: Bristol-Myers Squibb and AstraZeneca expand diabetes alliance through $7 Billion acquisition of Amylin Pharmaceuticals (2012)
2013: Bristol-Myers Squibb Foundation Awards More Than $3.2 Million for Veterans' Mental Health Needs
2014: Allied Minds, Bristol-Myers Squibb in unique collaboration to develop early-stage drug candidates from academia
2014: Bristol Myers Squibb Company Still Open To Buying Despite Two Failures (2014)
2014: Celldex, Bristol-Myers Cut Deal on Immuno-Oncology Combo Trial
2015: Five (non-cancer) areas Bristol-Myers Squibb is pursuing hard_MedCity News
2016: BMS Secures The Keys To Padlock_lifescivc
2016: Bristol-Myers Is Poised To Break Out In 2017 - Bristol-Myers Squibb Company (NYSE:BMY)
2016: Bristol-Myers Squibb to Acquire Padlock Therapeutics, Inc.
2016: Opdivo Misses In NSCLC: Implications For Bristol-Myers Squibb, Merck And Others - Bristol-Myers Squibb Company (NYSE:BMY)
2016: With $100 million buy, BMS targets "richest opportunity for blockbuster drugs"
2017: Bristol-Myers Squibb: A Deep Dive Finds Some Pearls - Bristol-Myers Squibb Company (NYSE:BMY)
2017: Implications Of The Latest Smash In Bristol-Myers Squibb Stock - Bristol-Myers Squibb Company (NYSE:BMY)
2017: VA_65--Bristo-Myers Squibb & Gilead Sciences, LLC Contract Award Effective 2/15/2017
2018: Bristol-Myers and Nektar Therapeutics team up to develop cancer combination treatments across nine tumor types; Nektar down 5% premarket_seekingalpha.com
2018: Illumina, Bristol-Myers Squibb Partner on Companion Dx Development for Immunotherapy
2018: Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results - Advaxis Inc. (NASDAQ:ADXS)
2019: Bristol-Meyers Squibb Acquisition Of Celgene Is Brilliant - Bristol-Myers Squibb Company (NYSE:BMY)
2019: Bristol-Myers Squibb: 2020 Total Return Play With A 2.8% Dividend Yield_seekingalpha.com
2020: 3 Reasons Bristol-Myers Squibb Could Make You Rich
2020: Bristol Myers CEO Caforio on coronavirus R&D: Let’s make it a ‘new standard for collaboration’
2021: After Many Delays, BMS and bluebird Win Approval for Multiple Myeloma CAR-T
2022: Bristol Myers has change of heart on cardiovascular gene therapy pact, terminating uniQure deal
2022: Bristol Myers Squibb: Still A Buy Despite Some Concerns_seekingalpha.com
2022: Bristol-Myers Squibb Company 2022 Q1 - Results - Earnings Call Presentation_ seekingalpha.com
2022: Game over: Bristol Myers, Nektar end $3.6B immuno-oncology program after 2 more late-stage flops
2022: PathAI and Bristol Myers Squibb Expand AI Pact in Drug Discovery and Development
2023: Bristol Myers Squibb: Undervalued Already, But Could Go Lower
2023: Bristol Myers Squibb’s investments
2023: Bristol-Myers Squibb Acquisition Of Mirati Makes Sense
2023: Bristol-Myers Squibb: A Nice Deal For This Bargain Pharma Stock_seekingalpha.com
2023: Bristol-Myers Squibb: A Tough But Cheap Spot_seekingalpha.com
2023: Bristol-Myers Squibb: Cash Rich And Trades Under 10x PE_ seekingalpha.com
2023: Bristol-Myers Squibb: Time To Get Greedy 7(NYSE:BMY)
2023: Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation_ seekingalpha.com
2023: Bristol-Myers: Out Of Favor (Rating Upgrade) (NYSE:BMY)
2024: 5 Reasons Bristol-Myers Squibb Looks Good Now (Rating Upgrade)
2024: A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology
2024: ASCO 2024 Round-Up: Some Of The Most Impactful Cancer News Out Of The Big Meeting
2024: Bayer: Why I'm Careful, But Rate It Buy_seekingalpha
2024: Behind the rise BMS’ Cobenfy, the first new schizophrenia drug in decades
2024: Beyond the Balance Sheet: What SWOT Reveals About Bristol-Myers Squibb Co (BMY)
2024: BMS' CAR-T cracks down on lupus, achieving sustained responses in phase 1
2024: BMS’ Cobenfy tipped to be top dog in growing schizophrenia space
2024: Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)
2024: Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)
2024: Bristol Myers Squibb: The Comeback Is Unfolding
2024: Bristol Myers Squibb's SWOT analysis: stock faces challenges amid pipeline promise
2024: Bristol Myers, 2seventy bio's Abecma approved for earlier line multiple myeloma
2024: Bristol-Myers Squibb (BMY): Growth Potential Amid Strategic Acquisitions and Revenue Increase
2024: Bristol-Myers Squibb Company (BMY): A Bull Case Theory
2024: Bristol-Myers Squibb Company 2023 Q4 - Results - Earnings Call Presentation
2024: Bristol-Myers Squibb Deserves Its Place Among Its Big Pharma Brethren
2024: Bristol-Myers Squibb Likely To Revalue Higher Following New Drug Approval
2024: Bristol-Myers Squibb Stock: Clearly Undervalued, Excellent 2H24 Culminates In Opdivo 'Subcu' Approval_seekingalpha.com
2024: Bristol-Myers Squibb Will Handle The Patent Cliff And Is Still Undervalued
2024: Bristol-Myers Squibb: A Better Earnings Outlook, Stronger Momentum Heading Into 2025
2024: Bristol-Myers Squibb: A Potential Comeback In Healthcare
2024: Bristol-Myers Squibb: A Potential Comeback In Healthcare_
2024: Bristol-Myers Squibb: All Focus On Execution
2024: Bristol-Myers Squibb: Buy This Bargain Before It's Gone
2024: Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)_ seekingalpha.com
2024: Bristol-Myers Squibb: Compelling Value From The New Products Portfolio And 4.5% Yield
2024: Bristol-Myers Squibb: Don't Waver Over Undue Fears And Doubts
2024: Bristol-Myers Squibb: Finally Trending Up
2024: Bristol-Myers Squibb: Massive Discount Spells Opportunity
2024: Bristol-Myers Squibb: Rich Dividends & Double-Digits Upside Potential - Bright 2026 Prospects_seekingalpha.com
2024: Bristol-Myers Squibb: Sell Now, Buy Later (Rating Downgrade)
2024: Bristol-Myers Squibb: Shares Getting Closer To The Tipping Point (Rating Downgrade)
2024: Bristol-Myers Squibb: Turnaround Expected
2024: Bristol-Myers Squibb: Unlocking Value With KarXT FDA Approval And Oncology Pipeline Progress
2024: Bristol-Myers Squibb: Unlocking Value With KarXT FDA Approval And Oncology Pipeline Progress_seekingalpha.com
2024: Bristol-Myers Squibb's Recent >$20bn M&A Spree Should Reward Patient Investors_ seekingalpha.com
2024: Fangzhou partners with Bristol Myers Squibb in China
2024: FDA Approval of Bristol Myers Drug Makes It the First Novel Schizophrenia Med in Decades
2024: FDA approves Bristol Myers Squibb’s schizophrenia drug, the first new type of treatment in decades_www.cnbc.com
2024: For Bristol Myers Squibb's newly approved schizophrenia drug, what a long, strange trip it's been
2024: Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
2024: Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases • Repertoire Immune Medicines
2024: U.S. FDA Approves Bristol Myers Squibb’s Breyanzi ® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
2024: US FDA approves Bristol Myers' schizophrenia drug
2025: #2. Eliquis (apixaban) Bristol Myers Squibb and Pfizer 2024 Sales: $20.699 billion ($13.333 billion BMS + $7.366 billion Pfizer) 2023 Sales: $18.953 billion ($12.206 billion BMS + $6.747 billion Pfizer) % Change: +9.2%
2025: Bristol-Myers And BioNTech Deal: Good For Both Parties, But One Is The Better Investment
2025: Bristol-Myers Squibb: Cobenfy's Strong Launch And 2025 Growth Outlook
2025: Bristol-Myers Squibb: Solid Q4 Earnings, But Weak Guidance And Patent Concerns Drive The Stock Down
2025: Bristol-Myers Squibb: Why I'm Still Bullish
2025: Cabaletta, Bristol Myers CAR-T therapies spur remissions in autoimmune disorders
2026: 44th Annual J.P. Morgan Healthcare Conference (NYSE:BMY) 2026-01-12
2026: ASCO: BMS’ CELMoD drug doubles PFS in ‘incredibly exciting’ ph. 3 myeloma study
2026: BMS, China's Hengrui Pharma partner to develop 13 drugs
2026: Bristol Myers Squibb: Rerating Was Fast - Proof Will Be Slow (BMY) (Rating Downgrade)
2026: Bristol Myers Squibb's Breakout Is Here: Portfolio Renewal Gaining Momentum
2026: U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse
Bristol Myers Squibb Foundation (BMSF)
Bristol Myers Squibb: New Product & Business Developments
Jumps
*Key People: Bristol Myers Squibb (BMS)
Finance & Acquisitions: Bristol Myers Squibb